High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy

The addition of 6 months of ADT to LDR brachytherapy for H-IR prostate cancer does not improve 5 year prostate specific antigen control, and we no longer routinely recommended it.